Licensing Package

The Non-Confidential Anti-thrombotic program licensing package is available to download.

Medicure is open to exploring collaborations for the further research & development of MC-1 and other pipeline compounds for cardiovascular conditions.

Licensing Opportunities

In-Licensing

Medicure maintains an interest in in-licensing and co-promoting cardiovascular brands and technologies. Medicure will identify and expand its portfolio of products to complement and broaden its focus in cardiovascular disease and to build on its existing expertise in cardiovascular biology, medicinal chemistry and clinical development.

Partnering

Medicure is open to exploring collaborations for the further research & development of MC-1 and other pipeline compounds for cardiovascular conditions.

The Company's business strategy and goal is to create optimal value for shareholders, building its own commercial capabilities and by establishing partnerships that provide a strong marketing presence and use proven development and commercialization expertise.

Medicure is seeking a partner to help support the development and commercialization of Tardoxal for Tardive Dyskinesia and related conditions. For information on this opportunity contact Dawson Reimer at dreimer@medicure.com